Argenx Expands Immunology Portfolio with $2.2B Buyout of Forte Biosciences
FB102Positive
AI Analysis
Summary
Argenx announced a $2.2B acquisition of Forte Biosciences, which recently reported positive Phase Ib data for FB102 (anti-CD122 monoclonal antibody) in vitiligo, achieving statistically significant facial improvement at week 24.
Clinical Trial Data
Phase
Ib
Primary Endpoint
Met
Importance:8/10
Sentiment:
0.75
M&Aimmunologymonoclonal antibodyvitiligoPhase Ib positivedermatology
Related Companies
Read the original article
Published by GEN - Genetic Engineering & Biotech News on July 28, 2026 7:46 PM